CSL
@CSL
Followers
6K
Following
2K
Media
766
Statuses
2K
Since our start in 1916, we have been driven by our promise to identify, develop and deliver innovations so our patients can live life to the fullest.
Melbourne, Victoria
Joined October 2015
Today we shared our full-year results for FY25. Take a look at some of the key financial and operational highlights. For more details visit our Investor Centre: #CSL #FullYearResults
0
2
6
Applications for the 2026 CSL Centenary Fellowships will close on 30 June. We are inviting Australia’s top early-mid career scientists to apply for next year’s fellowships now.
0
6
7
Innovation meets convenience with our first homegrown mAb to gain approval, offering a new option that may help patients manage their condition. We’re proud to bring this innovation to the HAE community.
0
1
4
RT @AusAmbCH: @CSL Behring exemplifies the enduring #partnership between Australia and Switzerland, merging Australian #innovation with Swi….
0
2
0
The U.S. FDA has approved the only once-monthly treatment targeting factor XIIa to prevent attacks of HAE. This reflects our commitment to HAE patients around the world, a community we have proudly supported for over four decades. Read more:
0
3
5
Dr @qizhang85 from @SAiGENCI, @UniofAdelaide is doing important #research with the support of a #CSLCentenaryFellowship. Applications for 2026 are now open:
0
1
2
.@DrClareWeeden from @WEHI_research is doing important #research with the support of a #CSLCentenaryFellowship. Applications for 2026 are now open: #CSL
0
2
6
Applications are open for the 2026 CSL Centenary Fellowships. Australian early-mid career biomedical #researchers are invited to apply for 1 of 2 A$1.25m #grants over 5 years.
0
3
4
Congratulations to the eight medical researchers who have been awarded a CSL Research Acceleration Initiative (RAI) partnership to fast-track the discovery of innovative biotherapies to address unmet medical needs.
0
2
3
CSL is proud to sponsor the symposium "WHO guidance on PBM implementation: Strategies for effective dissemination and communication" at @NATAforum. We look forward to welcoming you on Thursday 24 April at 12:15 CET!
0
1
4
Japan’s MHLW approved our first-in-class monoclonal antibody for HAE, reinforcing our commitment to a community we have supported for more than 40 years. Japan joins Australia, the UK, and the EU in offering an innovative treatment to patients. Learn more:
0
1
8
The European Commission’s approval of our first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of HAE reflects our ongoing commitment to improving the lives of people living with this condition.
0
1
9
Along with our partner @ArcturusRx, we are proud to announce that the EC has approved the first self-amplifying mRNA COVID-19 vaccine in the European Union. Read more:
0
3
4
Our first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of HAE is approved by the EC. We are committed to advancing care for people living with HAE, a community we have supported for over 40 years. Read more:
0
2
5
Our first approved homegrown recombinant mAb highlights our unwavering dedication to advancing care for those with HAE – a community we have supported for over 40 years. We are committed to improving the lives of patients around the world. Read more:
1
1
7
🎉✨ Cheers to a fresh start and endless possibilities! As we welcome 2025, let’s embrace new adventures, chase big dreams, and celebrate every moment along the way. Here’s to health, happiness, and success for all in the year ahead. 🥂🎆 #HappyNewYear #CSL
1
1
5